Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Overexpression of NK cell-activating ligand MICA/B correlates with superior outcomes and might be a therapeutic target for chemo-immunotherapy in non-small-cell lung cancer

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Riki Okita

Citation

Annals of Oncology (2015) 26 (suppl_9): 148-152. 10.1093/annonc/mdv533

Authors

R. Okita, T. Yukawa, Y. Nojima, A. Maeda, S. Saisho, K. Shimizu, M. Nakata

Author affiliations

  • General Thoracic Surgery, Kawasaki Medical School, 701-0192 - Kurashiki/JP
More

Resources

Abstract 794

Aim/Background

MICA and MICB (MICA/B) are the NK group 2 member D (NKG2D) ligands that are broadly expressed in transformed cells and promote natural killer (NK) cell-mediated cytotoxicity via NKG2D–NKG2D ligand interaction. NKG2D ligand overexpression has been recently reported to correlate with good prognosis in different types of cancer, however, the prognostic significance of MICA/B expression in NSCLC tissue has never been reported.

Methods

MICA/B expression was evaluated by immunohistochemistry in 91 consecutive NSCLC patients after radical surgery; the clinicopathological features as well as clinical outcome were also analyzed. Additionally, MICA/B expressions as well as NK cell-mediated cytotoxicity in NSCLC cell line A549 treated with chemotherapeutic regents were assessed by flowcytoetric analysis and LDH release assay, respectively.

Results

Overall, 28 of 91 (30.8%) specimens overexpressed MICA/B. The MICA/B overexpression was associated with low F18-fluorodeoxyglucose (FDG) uptake and adenocarcinoma histology. After a median follow-up of 48.2 months, MICA/B overexpression was associated with good recurrence-free survival (RFS) (p = 0.037). In multivariate analysis, MICA/B overexpression emerged as an independent prognostic factor for RFS (p = 0.046). In vitro assay, chemotherapeutic reagents upregulated MICA/B expression via ATM-ATR pathway, resulted in enhanced NK cell-mediated cytotoxicity in A549 cells.

Conclusions

MICA/B overexpression in patients with radically resected NSCLC is predictive of good prognosis, and chemotherapeutic regent enhances NK cell-mediated cytotoxicity via upregulation of MICA/B.

Clinical trial identification

Disclosure

M. Nakata: research fundings from Kyowa-Kirin, Eli Lilly Japan and CSL Behring. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings